Your browser doesn't support javascript.
loading
Robust and prototypical immune responses toward influenza vaccines in the high-risk group of Indigenous Australians.
Hensen, Luca; Nguyen, Thi H O; Rowntree, Louise C; Damelang, Timon; Koutsakos, Marios; Aban, Malet; Hurt, Aeron; Harland, Kim L; Auladell, Maria; van de Sandt, Carolien E; Everitt, Anngie; Blacker, Cath; Oyong, Damian A; Loughland, Jessica R; Webb, Jessica R; Wines, Bruce D; Hogarth, P Mark; Flanagan, Katie L; Plebanski, Magdalena; Wheatley, Adam; Chung, Amy W; Kent, Stephen J; Miller, Adrian; Clemens, E Bridie; Doherty, Peter C; Nelson, Jane; Davies, Jane; Tong, Steven Y C; Kedzierska, Katherine.
Affiliation
  • Hensen L; Department of Microbiology and Immunology, University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Parkville, VIC 3000, Australia.
  • Nguyen THO; Department of Microbiology and Immunology, University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Parkville, VIC 3000, Australia.
  • Rowntree LC; Department of Microbiology and Immunology, University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Parkville, VIC 3000, Australia.
  • Damelang T; Department of Microbiology and Immunology, University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Parkville, VIC 3000, Australia.
  • Koutsakos M; Department of Microbiology and Immunology, University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Parkville, VIC 3000, Australia.
  • Aban M; World Health Organization Collaborating Centre for Reference and Research on Influenza, The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
  • Hurt A; World Health Organization Collaborating Centre for Reference and Research on Influenza, The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
  • Harland KL; Department of Microbiology and Immunology, University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Parkville, VIC 3000, Australia.
  • Auladell M; Department of Microbiology and Immunology, University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Parkville, VIC 3000, Australia.
  • van de Sandt CE; Department of Microbiology and Immunology, University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Parkville, VIC 3000, Australia.
  • Everitt A; Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, 1066 CX Amsterdam, The Netherlands.
  • Blacker C; Menzies School of Health Research, Charles Darwin University, Darwin, NT 0810, Australia.
  • Oyong DA; Menzies School of Health Research, Charles Darwin University, Darwin, NT 0810, Australia.
  • Loughland JR; Menzies School of Health Research, Charles Darwin University, Darwin, NT 0810, Australia.
  • Webb JR; Center for Global Infectious Disease Research (CGIDR), Seattle Children's Research Institute, Seattle, WA 98109.
  • Wines BD; Menzies School of Health Research, Charles Darwin University, Darwin, NT 0810, Australia.
  • Hogarth PM; Immunology Group, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4029, Australia.
  • Flanagan KL; Menzies School of Health Research, Charles Darwin University, Darwin, NT 0810, Australia.
  • Plebanski M; Immune Therapies Laboratory, Burnet Institute, Melbourne, VIC 3084, Australia.
  • Wheatley A; Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC 3010, Australia.
  • Chung AW; Department of Clinical Pathology, The University of Melbourne, Parkville, VIC 3010, Australia.
  • Kent SJ; Immune Therapies Laboratory, Burnet Institute, Melbourne, VIC 3084, Australia.
  • Miller A; Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC 3010, Australia.
  • Clemens EB; Department of Clinical Pathology, The University of Melbourne, Parkville, VIC 3010, Australia.
  • Doherty PC; Tasmanian Vaccine Trial Centre, Clifford Craig Foundation, Launceston General Hospital, Launceston, TAS 7250, Australia.
  • Nelson J; School of Health Sciences and School of Medicine, University of Tasmania, Launceston, TAS 7248, Australia.
  • Davies J; Department of Immunology and Pathology, Monash University, Melbourne, VIC 3800, Australia.
  • Tong SYC; School of Health and Biomedical Science, Royal Melbourne Institute of Technology, Melbourne, VIC 3000, Australia.
  • Kedzierska K; School of Health and Biomedical Science, Royal Melbourne Institute of Technology, Melbourne, VIC 3000, Australia.
Proc Natl Acad Sci U S A ; 118(41)2021 10 12.
Article in En | MEDLINE | ID: mdl-34607957
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Influenza Vaccines / Lymphocyte Activation / Influenza, Human / Indigenous Peoples / Antibodies, Viral Type of study: Etiology_studies / Observational_studies / Risk_factors_studies Limits: Humans Country/Region as subject: Oceania Language: En Journal: Proc Natl Acad Sci U S A Year: 2021 Type: Article Affiliation country: Australia
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Influenza Vaccines / Lymphocyte Activation / Influenza, Human / Indigenous Peoples / Antibodies, Viral Type of study: Etiology_studies / Observational_studies / Risk_factors_studies Limits: Humans Country/Region as subject: Oceania Language: En Journal: Proc Natl Acad Sci U S A Year: 2021 Type: Article Affiliation country: Australia